Technetium Containing (at. No. 43; Tc) Patents (Class 534/14)
-
Publication number: 20120208988Abstract: Compounds of Formula (Ia) wherein R is a C6-C12 substituted or unsubstituted aryl, a C6-C12 substituted or unsubstituted heteroaryl, a C1-C6 substituted or unsubstituted alkyl or —NR?R?, Q is C(O), O, NR?, S, S(O)2, C(O)2 (CH2)p Y is C(O), O, NR?, S, S(O)2, C(O)2 (CH2)p Z is H or C1-C4 alkyl, R? is H, C(O), S(O)2, C(O)2, a C6-C12 substituted or unsubstituted aryl, a C6-C12 substituted or unsubstituted heteroaryl or a C1-C6 substituted or unsubstituted alkyl, when substituted, aryl, heteroaryl and alkyl are substituted with halogen, C6-C12 heteroaryl, —NR?R? or COOZ, which have diagnostic and therapeutic properties, such as the treatment and management of prostate cancer and other diseases related to NAALADase inhibition. Radiolabels can be incorporated into the structure through a variety of prosthetic groups attached at the X amino acid side chain via a carbon or hetero atom linkage.Type: ApplicationFiled: November 11, 2011Publication date: August 16, 2012Applicant: MOLECULAR INSIGHTS PHARMACEUTICALS, INC.Inventors: John W. Babich, Craig N. Zimmerman, Kevin P. Maresca
-
Patent number: 8232360Abstract: The invention relates to stereoregular ROMP polymers, the monomers used to make them, and the processes used to convert the monomers to the polymers.Type: GrantFiled: July 17, 2007Date of Patent: July 31, 2012Assignee: Research Foundation of State University of N.Y.Inventors: Nicole S. Sampson, Kathlyn A. Parker
-
Patent number: 8211402Abstract: A compound that recognizes and binds to the CA-IX protein has Formula I, II, III, or IV. The compounds may include a radioactive element for radioimaging or therapeutic applications. Thus, pharmaceutical compositions may be prepared with one or more of the compounds of Formula I, II, III, or IV.Type: GrantFiled: December 4, 2009Date of Patent: July 3, 2012Assignee: Molecular Insight Pharmaceuticals, Inc.Inventors: John W. Babich, Craig Zimmerman, John Joyal, Kevin P. Maresca, Genliang Lu, Shawn Hillier
-
Patent number: 8211401Abstract: A compound of Formula I, a pharmaceutically acceptable salt, or solvate thereof: complexes with metals such as rhenium, technetium, and others to provide a complex for imaging tissues or treating disease, particularly where the metal is radioactive. Such complexes are specific to PSMA protein and can therefore be used in imaging or treating cancer of the prostate and other tissue where the protein is expressed.Type: GrantFiled: December 4, 2009Date of Patent: July 3, 2012Assignee: Molecular Insight Pharmaceuticals, Inc.Inventors: John W. Babich, Craig Zimmerman, John Joyal, Kevin P. Maresca, Genliang Lu, Shawn Hillier
-
Publication number: 20120142641Abstract: The present invention relates to a complex of a bisphosphonate compound, methods of preparing such complex and uses thereof.Type: ApplicationFiled: June 7, 2010Publication date: June 7, 2012Applicant: NANYANG TECHNOLOGICAL UNIVERSITYInventors: Subramanian Venkatraman, Say Chye Joachim Loo
-
Publication number: 20120128583Abstract: The present invention relates to DTPA derivatives capable of forming complexes by combining with metals and the like, metal complexes formed by combining with the DTPA derivatives, MR and CT contrast agents including gold (Au) nano-particles of which surfaces are coated with the metal complexes, and a method for manufacturing the same. The MR and CT contrast agents according to the present invention have a high magnetic relaxation rate, thereby providing an excellent contrast enforcement effect and a long image acquisition time. Furthermore, the MR and CT contrast agents are not toxic to the human body, and are image contrast agents of dual molecules capable of being applied to both MR and CT.Type: ApplicationFiled: December 13, 2009Publication date: May 24, 2012Applicant: Kyungpook National University Industry Academic Cooperation FoundationInventors: Tae Jung Kim, Yong Min Jang, Ji Ae Park
-
Publication number: 20120093725Abstract: The present invention relates to the diagnosis of clinical conditions characterized by undesirable and/or abnormal selectin expression. In particular, the invention provides for the use of fucoidans for the detection of selectins using imaging techniques including ultrasonography, scintigraphy and MRI. Selectin-targeted imaging agents are provided that comprise at least one fucoidan moiety associated with at least one detectable moiety. Methods and kits are described for using these imaging agents in the diagnosis of clinical conditions such as thrombosis, myocardial ischemia/reperfusion injury, stroke and ischemic brain trauma, neurodegenerative disorders, tumor metastasis and tumor growth, and rheumatoid arthritis.Type: ApplicationFiled: April 10, 2009Publication date: April 19, 2012Applicant: Inserm (Institut National de la Sante et de la Recherche MedicaleInventors: Jean-Baptiste Michel, Didier Letourneur, Frederic Chaubet, Laure Bachelet, Francois Rouzet, Alain Meulemans
-
Publication number: 20120077967Abstract: Novel radioactive technetium and rhenium complexes comprising tripodal ligands are provided by the present invention. In particular, Tc(I) complexes are provided by the present invention. Novel ligands suitable for the formation of the technetium and rhenium complexes of the invention are also provided, as well as radiopharmaceutical compositions comprising said complexes, kits for their preparation. The invention also relates to the use of 99mTc radiopharmaceuticals of the invention for SPECT imaging.Type: ApplicationFiled: September 14, 2011Publication date: March 29, 2012Applicant: GE HEALTHCARE LIMITEDInventor: RAJIV BHALLA
-
Patent number: 8119103Abstract: The present invention is directed to metal chelating conjugates for use as metallopharmaceutical diagnostic or therapeutic agents. Specifically, conjugates of the present invention include one or more carriers, a linker, and metal coordinating moiety comprising a resorcinol, thioresorcinol, or dithioresorcinol derivative through which the metal coordinating moiety is bonded to the linker.Type: GrantFiled: February 20, 2007Date of Patent: February 21, 2012Assignee: Mallinckrodt LLCInventor: Dennis A. Moore
-
Publication number: 20110300072Abstract: Use of benzimidazole-derived compounds of formula (I) according to the following structure, wherein x is a heteroatom selected from N, S, O, P, SO, SO2 and SO3, preferably from N, S and SO3 and most preferably from N and SO3; n may be 0 or 1, R1 is a group selected from formula (II) and formula (III) and R2 is a group selected from H and formula (IV) since the aforesaid serves for the production of a formulation used as a specific marker in the case of neurodegenerative diseases and tau pathologies.Type: ApplicationFiled: July 22, 2009Publication date: December 8, 2011Applicant: SERVICIOS CIENTIFICOS NEUROINNOVATION LTDA.Inventors: Ricardo Maccioni Baraona, Leonel Rojo, Rodrigo Kuljis Azocar
-
Patent number: 8048405Abstract: A radioactive mixture and a manufacturing method thereof are disclosed. The radioactive mixture (188Re-MN/Lipiodol mixture) is formed by chelating reaction of MN series compounds that are amine-amide-disulfide amine quadric-dentate chelate ligands with TcO4?/or ReO4?, and then dissolved in Lipiodol. Moreover, the 99mTc/or 188Re of the TcO4?/or ReO4? avoids bone marrow injuries caused by free 90Y. By the feature of the Lipiodol that stays in liver tumors for a long period, the radioactive mixture is applied to treat liver cancers by injection so that injuries caused by surgical operations can be prevented. 188Re-MN/Lipiodol is used for liver cancer, breast cancer or other solid tumors treatment. Re-188 MN or Re-188 MN/Lipiodol can be mixed with anticancer drugs, hydrogel, liposome, micelle or other nano-particles to form the multifunctional therapeutic modality.Type: GrantFiled: January 16, 2009Date of Patent: November 1, 2011Assignee: Atomic Energy Council-Institute of Nuclear Energy ResearchInventors: Tsai-Yueh Luo, I-Chung Tang, Show-Wen Liu, Yu-Lung Wu, Cheng-Hsien Lin, Cheng-Fang Hsu, Kwei-Luen Hsu, Chang-Mau Sheng, Ching-Jun Liou, Te-Sheng Liang
-
Publication number: 20110262347Abstract: Disclosed are compositions and methods related to multivalent compositions targeted to cells and tissues. The disclosed targeting is useful for treatment of cancer and other diseases and disorders.Type: ApplicationFiled: April 8, 2011Publication date: October 27, 2011Inventors: Erkki Ruoslahti, Lilach Agemy, Dinorah Friedmann-Morviniski, Venkata Ramana Kotamraju, Kazuki Sugahara, Inder Verma
-
Publication number: 20110251363Abstract: The invention relates to stereoregular ROMP polymers, the monomers used to make them, and the processes used to convert the monomers to the polymers.Type: ApplicationFiled: July 17, 2007Publication date: October 13, 2011Inventors: Nicole S. Sampson, Kathlyn A. Parker
-
Publication number: 20110236312Abstract: The invention provides compounds that comprise a 4?-thio nucleoside that is a derivative of 4?-thiothymidine or 4?-thio-2?-deoxyuridine comprising a positron or single photon emitting radioisotope or corresponding non-radioactive isotope attached via a triazole link to the N-3 position. Methods for preparing such compounds and uses of the compounds in medicine are also provided.Type: ApplicationFiled: August 28, 2009Publication date: September 29, 2011Applicant: IMPERIAL INNOVATIONS LIMITEDInventors: Eric Ofori Aboagye, Graham Smith
-
Publication number: 20110236308Abstract: The present invention relates generally to chelation compounds, radionuclide metal chelate compounds, i.e., complexes, and radiolabeled targeting moieties, i.e., conjugates, formed therefrom, and methods of using these compounds, complexes and conjugates for diagnostic and therapeutic purposes. This invention is more particularly related to aryl bidentate isonitrile metal complexes generated by a chemical interaction of a metal salt oxide or weak complex of the metal with aryl isonitrile bidentate ligands.Type: ApplicationFiled: April 17, 2007Publication date: September 29, 2011Applicant: The General Hospital CorporationInventors: David R. Elmaleh, Timothy M. Shoup, Alan J. Fischman, Bhaskar C. Das
-
Publication number: 20110229410Abstract: One aspect of the invention relates to novel complexes of technetium (Tc) with various heteroaromatic ligands, e.g., pyridyl and imidazolyl ligands, and their use in radiopharmaceuticals for a variety of clinical diagnostic and therapeutic applications. Another aspect of the invention relates to novel pyridyl ligands that form a portion of the aforementioned complexes. Methods for the preparation of the technetium complexes are also described. Another aspect of the invention relates to novel pyridyl ligands based on derivatized lysine, alanine and bis-amino acids for conjugation to small peptides by solid phase synthetic methods. Additionally, the invention relates to methods for imaging regions of a mammal using the complexes of the invention.Type: ApplicationFiled: January 20, 2011Publication date: September 22, 2011Inventors: John W. Babich, Kevin P. Maresca
-
Patent number: 8022211Abstract: Novel radioactive technetium and rhenium complexes comprising tripodal ligands are provided by the present invention. In particular, Tc(I) complexes are provided by the present invention. Novel ligands suitable for the formation of the technetium and rhenium complexes of the invention are also provided, as well as radiopharmaceutical compositions comprising said complexes, kits for their preparation. The invention also relates to the us of 99mTc radiopharmaceuticals of the invention for SPECT imaging.Type: GrantFiled: October 4, 2005Date of Patent: September 20, 2011Assignee: GE Healthcare LimitedInventor: Rajiv Bhalla
-
Publication number: 20110206604Abstract: A hypoxia contrast medium including nitroimidazole-amino acid chelate with a positively charged radioactive nuclide, a preparation method and use thereof. The contrast medium can be used in imaging cerebral thrombosis, tumors or other diseases such as ulceration, thrombosis, and so on.Type: ApplicationFiled: April 29, 2011Publication date: August 25, 2011Inventor: Jianping Ruan
-
Publication number: 20110168984Abstract: Porphyrin compounds are provided. The compounds may further comprise a fused polycyclic aromatic hydrocarbon or a fused heterocyclic aromatic. Fused polycyclic aromatic hydrocarbon s and fused heterocyclic aromatics may extend and broaden absorption, and modify the solubility, crystallinity, and film-forming properties of the porphyrin compounds. Additionally, devices comprising porphyrin compounds are also provided. The porphyrin compounds may be used in a donor/acceptor configuration with compounds, such as C60.Type: ApplicationFiled: August 25, 2010Publication date: July 14, 2011Applicants: The Regents of the University of Michigan, The University of Southern CaliforniaInventors: Stephen R. Forrest, Jeramy D. Zimmerman, Mark E. Thompson, Viacheslav Diev, Kenneth Hanson
-
Publication number: 20110160579Abstract: A device for the investigation of an object uses a microwave transmitter, a microwave receiver, a control device and a contrast medium. The microwave transmitter and the microwave receiver are controlled by the control device. In one embodiment, the following steps maybe implemented: introduction of the contrast medium into the object under investigation; transmission of a microwave signal into the object under investigation by the microwave transmitter; scattering of the microwave signal by the object under investigation and by the contrast medium; and/or reception of the scattered microwave signal by the microwave receiver.Type: ApplicationFiled: June 2, 2009Publication date: June 30, 2011Applicant: ROHDE & SCHWARZ GMBH & CO. KGInventors: Martin Leibfritz, Gerd Hechtfischer, René Krupka, Jan Prochnow
-
Publication number: 20110158907Abstract: This invention relates to a method of imaging amyloid deposits and to diphenyl-heteroaryl compounds, and methods of making radiolabeled diphenyl-heteroaryl compounds useful in imaging amyloid deposits. This invention also relates to compounds, and methods of making compounds for inhibiting the aggregation of amyloid proteins to form amyloid deposits, and a method of delivering a therapeutic agent to amyloid deposits.Type: ApplicationFiled: April 18, 2008Publication date: June 30, 2011Applicant: The Trustees of the Univeristy of PennsylvaniaInventors: Hank F. Kung, Mei-Ping Kung, Wenchao Qu
-
Publication number: 20110144483Abstract: The present invention provides novel amino acid compounds useful in detecting and evaluating brain and body tumors. These compounds have the advantageous properties of rapid uptake and prolonged retention in tumors and can be labeled with halogen isotopes such as fluorine-18, iodine-123, iodine-124, iodine-125, iodine-131, bromine-75, bromine-76, bromine-77, bromine-82, astatine-210, astatine-211, and other astatine isotopes. These compounds can also be labeled with technetium and rhenium isotopes using known chelation complexes. The compounds disclosed herein bind tumor tissues in vivo with high specificity and selectivity when administered to a subject. Preferred compounds show a target to non-target ratio of at least 2:1, are stable in vivo and substantially localized to target within 1 hour after administration. Preferred compounds include 1-amino-2-[18F]fluorocyclobutyl-1-carboxylic acid (2-[18F]FACBC) and 1-amino-2-[18F]fluoromethylcyclobutyl-1-carboxylic acid (2-[18F]FMACBC).Type: ApplicationFiled: November 15, 2010Publication date: June 16, 2011Inventor: Mark M. GOODMAN
-
Publication number: 20110097265Abstract: A test indicator for quantifying remaining liver function is provided. A novel liver receptor imaging agent with liver targeting property is utilized to develop a method for quantifying remaining liver function to serve as test indicator for judging the liver failure outcome in clinic, particularly for judging the necessity of liver transplantation for patients with liver failure or liver disease. The radioactivity uptake of the test indicator was negatively correlated with the extent of liver reserve. The cutoff value of liver reserve for liver transplantation is also disclosed.Type: ApplicationFiled: May 13, 2010Publication date: April 28, 2011Applicant: Institute of Nuclear Energy Research Atomic Energy Council, Executive YuanInventors: Mei-Hui Wang, Wuu-Jyh Lin, Chuan-Yi Chien, Hung-Man Yu, Reiko Takasaka Lee, Yuan-Chuan Lee
-
Patent number: 7922998Abstract: New and improved compounds for use in diagnostic imaging or therapy having the formula M-N—O—P-G, wherein M is a metal chelator having the structure: wherein R1-R5 and FG are as defined herein (in the form complexed with a metal radionuclide or not), N—O—P is the linker containing at least one non-alpha amino acid with a cyclic group, at least one substituted bile acid or at least one non-alpha amino acid, and G is the GRP receptor targeting peptide. In the preferred embodiment, M is an Aazta metal chelator or a derivative thereof. Methods for imaging a patient and/or providing radiotherapy or phototherapy to a patient using the compounds of the invention are also provided. Methods and kits for preparing a diagnostic imaging agent from the compound is further provided. Methods and kits for preparing a radiotherapeutic agent are further provided.Type: GrantFiled: June 24, 2005Date of Patent: April 12, 2011Assignee: Bracco Imaging S.p.A.Inventors: Enrico Cappelletti, Luciano Lattuada, Karen E. Linder, Edmund Marinelli, Palaniappa Nanjappan, Natarajan Raju, Kondareddiar Ramalingam, Rolf E. Swenson, Michael Tweedle
-
Publication number: 20110065904Abstract: H3LMN series compounds used as radioactive agents for treatment of liver cancer and a manufacturing method thereof are revealed. 2-thioethylamine hydrochloride is reacted with triphenylmethanol for protection of thiol to obtain 2-[(triphenylmethyl)thio]ethylamine. Then obtain N-[2-((triphenylmethyl)thio)ethyl]chloroacetamide by a transamidation reaction between 2-[(triphenylmethyl)thio]ethylamine and chloroactyl chloride. Next produce a amine-amide-thiol ligand-N-[2-((triphenylmethyl)thio)ethyl][2-((triphenylmethyl)thio)ethylamino]acetamide by a substitution reaction of N-[2-((triphenylmethyl)thio)ethyl]chloroacetamide and 2-[(triphenylmethyl)thio]ethylamine. After respective reaction with 1-bromotetradecane, 1-bromohexadecane and ethyl 16-bromohexadecanoate, H3LMN series compounds are obtained. These amine-amide-dithiols quadridentate ligands can react with MO3+ (M=Tc or Re) to produce electrically neutral complexes.Type: ApplicationFiled: September 14, 2009Publication date: March 17, 2011Inventors: Show-Wen Liu, Cheng-Hsien Lin, Tsyh-Lang Lin, Cheng-Fang Hsu
-
Publication number: 20110065680Abstract: A method for synthesizing a complex having the formula: [L3MO3]? wherein L3 represents a tridentate ligand, M represents a metal selected from Tc an Re, and n is a charge from ?2 to +1, the method comprising: a) reaction of pertechnetate or perrhenate with a reducing agent and L3, or b) reaction of pertechnetate or perrhenate with a Lewis acid and L3, wherein the synthesis (a) or (b) is carried out in an aqueous medium.Type: ApplicationFiled: March 10, 2009Publication date: March 17, 2011Inventors: Roger Alberto, Henrik Braband
-
Publication number: 20110064657Abstract: The prostate-specific membrane antigen (PSMA) is increasingly recognized as a viable target for imaging and therapy of cancer. Various 99mTc/Re-labeled compounds were prepared by attaching known Tc/Re chelating agents to an amino-functionalized PSMA inhibitor with or without a variable length linker moiety. Ex vivo biodistribution and in vivo imaging demonstrated the degree of specific binding to engineered PSMA+ PC3 PIP tumors.Type: ApplicationFiled: June 26, 2008Publication date: March 17, 2011Applicant: The Johns Hopkins UniversityInventors: Martin Gilbert Pomper, Ray Sangeeta, Ronnie C. Mease, Catherine Foss
-
Patent number: 7893223Abstract: Compounds of general formula (I): with substituents as defined herein and their chelates with bi-trivalent ions of the metal elements of atomic numbers 20 to 31, 39, 42, 43, 44, 49, and 57 to 83, and radioisotopes chosen among 203Pb, 67Ga, 68Ga, 72As, 111In, 113In, 90Y, 97Ru, 62Cu, 64Cu, 52Fe, 52mMn, 140La, 175Yb, 153Sm, 166Ho, 149Pm, 177Lu, 142Pr, 159Gd, 212Bi, 47Sc, 149Pm, 67Cu, 111Ag, 199Au, 161Tb, 51Cr, 167Tm, 141Ce, 168Yb, 88Y, 165Dy, 166Dy, 97Ru, 103Ru, 186Re, 99mTc, 211Bi, 213Bi, 214Bi, 105Rh, 109Pd, 177mSn, 177Sn and 199Au, as well as the salts thereof with physiologically compatible bases or acids.Type: GrantFiled: June 24, 2005Date of Patent: February 22, 2011Assignee: Bracco Imaging S.p.A.Inventors: Giovanni Battista Giovenzana, Giovanni Palmisano, Massimo Sisti, Camilla Cavallotti, Silvio Aime, Luisella Calabi, Rolf Swenson, Ramalingam Kondareddiar, Luciano Lattuada, Pierfrancesco Morosini
-
Publication number: 20100254906Abstract: New pharmaceutical compositions based on grafted polysaccharides and methods of preparing such compositions are provided. Methods of using the compositions in medical imaging—for example in scintigraphy and in internal radiotherapy—are also provided.Type: ApplicationFiled: July 25, 2008Publication date: October 7, 2010Applicant: LABORATOIRES CYCLOPHARMAInventors: Benoît Denizot, Franck Lacoeuille, Jean Jacques Le Jeune, François Hindre
-
Patent number: 7803351Abstract: Novel blood-brain barrier permeant amyloid-targeting peptides and peptide conjugates are described. The peptide conjugates include a radioisotope or other label in a stable complex that translocates across brain capillary endothelial cell monolayers. The labeled peptide conjugate binds to amyloid plaques (A?) associated with Alzheimer's disease, and is useful for the targeted delivery of therapeutic and diagnostic molecules into the brain.Type: GrantFiled: August 19, 2005Date of Patent: September 28, 2010Assignee: Washington UniversityInventors: Vijay Sharma, David Piwnica-Worms
-
Publication number: 20100228012Abstract: The disclosure provides pendant fatty acid compounds for use in diagnostic imaging, (particularly the cardiovascular system), as well as kits comprised of the same. The disclosure also provides for a method administering a imaging agent with a high specificity for the myocardium.Type: ApplicationFiled: June 4, 2009Publication date: September 9, 2010Inventor: John W. BABICH
-
Publication number: 20100221181Abstract: The present invention relates to a method of differentially diagnosing different types of dementia. In particular, the method relates to the use of specific SPECT tracers for differentially diagnosing Alzheimer's disease, Lewy-Body Dementia, and Frontotemporal Dementia.Type: ApplicationFiled: September 23, 2008Publication date: September 2, 2010Applicant: KONINKLIJKE PHILIPS ELECTRONICS N.V.Inventor: Frank Olaf Thiele
-
Patent number: 7785566Abstract: The invention comprises pharmaceuticals of formula (I) Z-(L)n-V, wherein V denotes a peptide, L denotes an optional linker, Z denotes a group that optionally can carry an imaging moiety M, n denotes 0 or 1. The pharmaceuticals are active as therapeutic agents for the treatment of heart failure, cardiac arrhythmias and diseases were fibrosis is prominent such as COPD, liver fibrosis and atherosclerosis and are also useful as diagnostic agents for the diagnosis of heart failure and diseases were fibrosis is prominent such as COPD, liver fibrosis and atherosclerosis.Type: GrantFiled: November 5, 2004Date of Patent: August 31, 2010Assignee: GE Healthcare, Inc.Inventors: Alan Cuthbertson, Bard Indrevoll, Morten Eriksen
-
Publication number: 20100202965Abstract: The present invention relates to methods for imaging annulus fibrosus tissue and a quantitative measurement of its local concentration in a sample using an agent comprising the compound of Formula I, a 13C or 2H enriched compound of Formula I, an 19F-labeled derivative of Formula I, a metal-DOTA (1,4,7,10-tetra-azacyclododecane-N,N?,N?,N??-tetraacetic acid) complex of Formula I, or a radioisotope derivative of Formula I.Type: ApplicationFiled: February 12, 2009Publication date: August 12, 2010Applicant: General Electric CompanyInventors: Cristina Abucay Tan Hehir, Tiberiu Mircea Siclovan, Kenneth Michael Fish, Nicole Evelyn Barnhardt, John V. Frangioni, Carrie S. Vooght
-
Patent number: 7767796Abstract: The present invention provides tetra-amine chelator conjugates with biological targeting moieties, linked via a linker group and technetium complexes thereof as radiopharmaceuticals. The linker group is such that the chelator is mono-functionalized at the bridgehead position and provides both flexibility and a lack or aryl groups, to minimize lipophilicity and steric hulk. Protected versions of the chelators are provided which permit conjugation with a wide range of targeting molecules without interfering reactions with the amine nitrogens of the tetra-amine chelator. Syntheses of the functionalised chelators are described, together with bifunctional chelate precursors. Radiopharmaceutical compositions comprising the technetium metal complexes of the invention are described, together with non-radioactive kits for the preparation of such radiopharmaceuticals.Type: GrantFiled: July 19, 2005Date of Patent: August 3, 2010Assignee: GE Healthcare LimitedInventors: Anthony Eamonn Storey, Harry John Wadsworth, Nigel Anthony Powell, Philip Duncanson
-
Publication number: 20100183509Abstract: Complexes of heterocyclic radionuclides are prepared based upon ligands having substituted pyridyl and imidazolyl groups. The ligands are bifunctional, having amino acid residues that may act as a linker to a bioactive molecule, and a tridentate chelator that may complex the radionuclide. The bioactive molecule may be a peptide or somatostatin.Type: ApplicationFiled: December 4, 2009Publication date: July 22, 2010Inventors: John W. BABICH, Craig Zimmerman, John Joyal, Kevin P. Maresca, John Marquis, Genliang Lu, Jian-cheng Wang, Shawn Hillier
-
Publication number: 20100178246Abstract: A compound of Formula I, a pharmaceutically acceptable salt, or solvate thereof: complexes with metals such as rhenium, technetium, and others to provide a complex for imaging tissues or treating disease, particularly where the metal is radioactive. Such complexes are specific to PSMA protein and can therefore be used in imaging or treating cancer of the prostate and other tissue where the protein is expressed.Type: ApplicationFiled: December 4, 2009Publication date: July 15, 2010Inventors: John W. Babich, Craig Zimmerman, John Joyal, Kevin P. Maresca, Genliang Lu, Shawn Hillier
-
Publication number: 20100178247Abstract: A compound that recognizes and binds to the CA-IX protein has Formula I, II, III, or IV. The compounds may include a radioactive element for radioimaging or therapeutic applications. Thus, pharmaceutical compositions may be prepared with one or more of the compounds of Formula I, II, III, or IV.Type: ApplicationFiled: December 4, 2009Publication date: July 15, 2010Inventors: John W. Babich, Craig Zimmerman, John Joyal, Kevin P. Maresca, Genliang Lu, Shawn Hillier
-
Patent number: 7744853Abstract: Radiolabeled annexin and modified annexin conjugates useful for imaging vascular thrombi are described. Methods for making and using such radiolabeled annexin conjugates are also provided.Type: GrantFiled: September 27, 2005Date of Patent: June 29, 2010Assignee: Poniard Pharmaceuticals, Inc.Inventors: Sudhakar Kasina, John M. Reno, Alan R. Fritzberg, Jonathan Tait
-
Publication number: 20100160615Abstract: A bisphosphonoaminc compound represented by the following formula (I): wherein R1, R2, R3, R4 and R5 are independently an alkyl group having 1 to 6 carbon atoms, and n is an integer of 1 to 6, is extremely useful as an intermediate for preparing a technetium nitride complex for radiodiagnostic imaging.Type: ApplicationFiled: January 20, 2006Publication date: June 24, 2010Applicant: NIHON MED-PHYSICS CO., LTD.Inventors: Francesco Tisato, Fiorenzo Refosco, Cristina Bolzati, Stefania Agostini, Marina Porchia, Mario Cavazza-Ceccato, Shinji Tokunaga
-
Publication number: 20100143249Abstract: The present invention is directed towards novel folate-conjugates of formula I wherein F is a folate or derivative thereof, Z1, Z2, Z3 are independently of each other C or N, S1 to S4 are independently of each other a single bond or a spacer, Ra, Ra?, and Rb are donor groups and/or another group F, Rc is optionally another group F and n is 1 or 2. The invention further contemplates the corresponding metal-chelate complexes as well as pharmaceutical compositions thereof, and their uses in diagnostic imaging and radiotherapy.Type: ApplicationFiled: April 11, 2008Publication date: June 10, 2010Applicant: MERCK EPROVA AGInventors: Rudolf Moser, Roger Schibli, Cristina Magdalena Muller, Viola Groehn, Urs Michel, Christoph Sparr, Thomas Leighton Mindt
-
Patent number: 7731936Abstract: Provided are radiolytically and metabolically stable metal complexes based on tetrathiol ligands useful for nuclear medical diagnostics and in endoradionuclide therapy. Methods for their preparation are also provided. The complexes can have a central ligand, Y, that can be 99mTcO, 186ReO, 188ReO, 99mTcN, 186ReN or 188ReN.Type: GrantFiled: April 28, 2005Date of Patent: June 8, 2010Assignee: Forschungszentrum Rossendorf E,VInventors: Tobias Heinrich, Bernd Johannsen, Hans-Juergen Pietzsch, Sepp Seifert, Hartmut Spies
-
Patent number: 7718160Abstract: The invention, in one aspect, relates to radiolabeled compounds. The invention also relates to radiolabeled liposomes and methods of making and using thereof. The invention also relates to kits for preparing radiolabeled liposomes.Type: GrantFiled: May 22, 2003Date of Patent: May 18, 2010Assignee: The Board of Regents of the University of Texas SystemInventors: Ande Bao, William T. Phillips, Beth Goins
-
Publication number: 20100104512Abstract: The invention relates to dendritic chelated compounds, to methods for producing the same and to pharmaceutical compositions containing the same. The dendritic chelated complexes of the present invention have the following formula (I): [[MC]En-[D]m—X1p1X2p2X3p3X4p4]z? z B+ (I), where m is a magnetic or scintigraphic marker, C is a chelating agent of the marker M, E is a spacer, n=0 or 1, D is compound capable of forming a dendritic structure, m is an integer equal to 1 or 2 or 4, X1 is a group increasing the complex lipophily, p1 is an integer from 0 to 12, X2 is a group increasing the complex specificity for a particular organ, p2 is an integer equal to 1 or 2 or 4, X3 is a group having a therapeutic activity, p3 is an integer equal to 0, 1, 2 or 4, X4 is a CH3 group, p4 is an integer from 0 to 12, B is a counter-ion, z is an integer equal to 0, 1, 2, 3 or 4. The invention can be used in the field of pharmacy, more precisely in medical imaging.Type: ApplicationFiled: October 9, 2007Publication date: April 29, 2010Applicant: Centre National De La Recherche ScientifiqueInventors: Delphine Felder-Flesch, Jerome Steibel, Annabelle Bertin
-
Publication number: 20100074842Abstract: Chelators of the formulae (I), (II) and (III) and tricarbonyl complexes of radioisotopes of Tc and Re bound to them, for use in myocardial imaging.Type: ApplicationFiled: November 23, 2007Publication date: March 25, 2010Inventors: Isabel Rego Santos, Antonio Manuel Rocha Paulo
-
Publication number: 20100074843Abstract: The present application is directed to radiolabeled imaging agents comprising a radiolabel, and a substrate, pharmaceutical compositions comprising radiolabeled imaging agents, and methods of using the radiolabeled imaging agents. The present application is further directed to methods of preparing the radiolabeled imaging agent. Such imaging agents can used in imaging studies, such as Positron Emitting Tomography (PET) or Single Photon Emission Computed Tomography (SPECT).Type: ApplicationFiled: April 30, 2009Publication date: March 25, 2010Applicant: Siemens Medical Solutions USA, Inc.Inventors: Hartmuth C. Kolb, Joseph C. Walsh, Kai Chen, Umesh B. Gangadharmath, Gang Chen, Vani P. Mocharla, Dhanalakshmi Kasi, Peter J.H. Scott, Qianwa Liang
-
Patent number: 7674886Abstract: The present invention provides for substituted metal chelating compounds in which at least two of the chelating atoms are nitrogen which are directly attached to aromatic rings and one or more of those nitrogen atoms has attached thereto a substituent other than hydrogen, and methods for making and using these compounds.Type: GrantFiled: September 4, 2007Date of Patent: March 9, 2010Assignee: Poniard Pharmaceuticals, Inc.Inventor: Sudhakar Kasina
-
Publication number: 20100055035Abstract: The invention provides, in a general sense, a new labeling strategy employing 99mTc chelated with ethylenedicysteine (EC). EC is conjugated with a variety of ligands and chelated to 99mTc for use as an imaging agent for tissue-specific diseases. The drug conjugates of the invention may also be used as a prognostic tool or as a tool to deliver therapeutics to specific sites within a mammalian body. Kits for use in tissue-specific disease imaging are also provided.Type: ApplicationFiled: September 21, 2009Publication date: March 4, 2010Inventors: David J. Yang, Chun W. Liu, Dong-Fang Yu, E. Edmund Kim
-
Publication number: 20100040542Abstract: The present invention relates to improved chelator conjugates with biological targeting molecules, suitable for forming metal complexes with radiometals. The radiometal complexes, especially with the radiometal 99mTc, are useful as radiopharmaceuticals.Type: ApplicationFiled: October 1, 2009Publication date: February 18, 2010Applicant: GE HEALTHCARE LIMITEDInventors: COLIN MILL ARCHER, HARRY JOHN WADSWORTH, TORGRIM ENGELL
-
Patent number: RE43274Abstract: Provided herein are compounds for detection, diagnosis and treatment of target tissues or target compositions, including hyperproliferative tissues such as tumors, using photodynamic methods. In particular, photosensitizer compounds that collect in hyperproliferative tissue are provided. In another embodiment, compounds that absorb light at a wavelength of from about 700 to about 850 nm are provided. In a further embodiment, compounds that are detectable by magnetic resonance imaging are provided.Type: GrantFiled: January 23, 2009Date of Patent: March 27, 2012Assignee: Health Research, Inc.Inventors: Ravindra K. Pandey, William R. Potter, Thomas J. Dougherty